Author/Editor		Tankova, Tsvetalina; Senkus-Konefka, Elżbieta; Beloyartseva, Maria; Borštnar, Simona; Catrinoiu, Doina; Frolova, Mona; Hegmane, Alinta; Janež, Andrej; Krnić, Mladen; Vrdoljak, Eduard
Title		Management strategies for hyperglycemia associated with the α-selective PI3K inhibitor alpelisib for the treatment of breast cancer
Type		članek
Vol. and No.		Letnik 14, št. 7
Publication year		2022
Volume		str. 1-14
ISSN		2072-6694 - Cancers
Language		eng
Abstract		Alpelisib is an α-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2‐), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression on or after endocrine therapy. Hyperglycemia is an on-target effect of alpelisib affecting approximately 60% of treated patients, and sometimes necessitating dose reductions, treatment interruptions, or discontinuation of alpelisib. Early detection of hyperglycemia and timely intervention have a key role in achieving optimal glycemic control and maintaining alpelisib dose intensity to optimize the benefit of this drug. A glycemic support program implemented by an endocrinology‐oncology collaborative team may be very useful in this regard. Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium‐glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2‐, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.
Keywords		hiperglikemija rak dojke metastaski rak neželeni učinki hyperglycemia breast cancer metastatic breast cancer adverse effect